What is Baebies?
Headquartered in Durham, North Carolina, Baebies specializes in the research and development of digital microfluidics technology. The company is dedicated to transforming the landscape of newborn screening and pediatric testing by providing comprehensive diagnostic solutions that ensure early disease detection. By leveraging advanced microfluidic systems, Baebies enables healthcare providers to perform rapid, accurate, and cost-effective testing, which is essential for timely medical intervention in neonatal care. The company's market position is defined by its focus on bridging the gap between complex laboratory diagnostics and point-of-care accessibility, effectively serving the needs of hospitals and clinical laboratories worldwide.
How much funding has Baebies raised?
Baebies has raised a total of $43.6M across 7 funding rounds:
Other Financing Round
$500K
Private Equity
$13M
Private Equity
$12.8M
Private Equity
$12.8M
Debt
$1M
Debt
$1.5M
Debt
$2M
Other Financing Round (2015): $500K with participation from North Carolina Biotechnology Center
Private Equity (2015): $13M led by DUMAC, Cunning Capital, Duke Angel Network, Rex Health Ventures, Triad, and North Carolina Biotechnology Center
Private Equity (2016): $12.8M, investors not publicly disclosed
Private Equity (2018): $12.8M featuring BOE Technology and Rex Healthcare
Debt (2020): $1M backed by PPP
Debt (2021): $1.5M with participation from PPP
Debt (2025): $2.1M, investors not publicly disclosed
Key Investors in Baebies
North Carolina Biotechnology Center
NCBiotech is a leader in life science economic development in North Carolina, focusing on transforming ideas from research into marketable products.
Rex Healthcare
UNC REX Healthcare, founded in 1894 and headquartered in Raleigh, North Carolina, is a private, not-for-profit health care system.
DUMAC
DUMAC Business Systems, Inc. is a leading solutions provider of point-of-sale software, hardware, and services to the independent grocery and restaurant industries.
What's next for Baebies?
With the successful closure of this major strategic investment, Baebies is well-positioned to expand its operational footprint and enhance its product pipeline. The company is expected to prioritize the commercialization of its next-generation screening platforms, aiming to increase the throughput and diagnostic sensitivity of its existing technology. Furthermore, the strategic allocation of these funds will likely support the scaling of manufacturing capabilities and the pursuit of additional regulatory clearances, ensuring that Baebies remains at the forefront of medical technology innovation. As the firm moves into its next phase of growth, the focus will remain on fostering strategic partnerships within the healthcare ecosystem to drive the widespread adoption of its diagnostic tools.
See full Baebies company page
